I-Mab Biopharma Announces Dosing of First Patient in a Pivotal Study of TJ202/MOR202 in Multiple Myeloma in Mainland China

[In The News]

SHANGHAI, Jan. 3, 2020 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a global biopharmaceutical company based in China and the United States and focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases today announced the...

View the full article